author-photo

Kirsi Launonen

6

Papers

34

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

P-029: 1st line combination treatment with proteasome-inhibitor and zoledronic acid is effective in reducing later fractures in multiple myeloma irrespective of MM bone disease

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.

2016 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (30)
RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow

2016 Blood
Show All
- Source
- Cite
- Save
Citations (4)
A randomized phase II study of stem cell mobilization with cyclophosphamide + G-CSF versus G-CSF alone after lenalidomide-based induction in multiple myeloma

2015 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A Randomized Comparison of Low-Dose Cyclophosphamide + G-CSF Versus G-CSF Alone Mobilization after Lenalidomide-Bortezomib-Dexamethasone (RVD) Induction in Multiple Myeloma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (0)